Cystic Fibrosis - Pipeline Review, H2 2017

Date: September 30, 2017
Pages: 387
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C278BF4B5BEEN
Leaflet:

Download PDF Leaflet

Cystic Fibrosis - Pipeline Review, H2 2017
Cystic Fibrosis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Pipeline Review, H2 2017, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 3, 32, 22, 57, 27 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 6, 7 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Cystic Fibrosis - Overview
Cystic Fibrosis - Therapeutics Development
Cystic Fibrosis - Therapeutics Assessment
Cystic Fibrosis - Companies Involved in Therapeutics Development
Cystic Fibrosis - Drug Profiles
Cystic Fibrosis - Dormant Projects
Cystic Fibrosis - Discontinued Products
Cystic Fibrosis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Cystic Fibrosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Cystic Fibrosis - Pipeline by 4D Molecular Therapeutics Inc, H2 2017
Cystic Fibrosis - Pipeline by Achaogen Inc, H2 2017
Cystic Fibrosis - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2017
Cystic Fibrosis - Pipeline by Alaxia SAS, H2 2017
Cystic Fibrosis - Pipeline by AlgiPharma AS, H2 2017
Cystic Fibrosis - Pipeline by Antabio SAS, H2 2017
Cystic Fibrosis - Pipeline by Apteeus, H2 2017
Cystic Fibrosis - Pipeline by Arch Biopartners Inc, H2 2017
Cystic Fibrosis - Pipeline by Arcturus Therapeutics Inc, H2 2017
Cystic Fibrosis - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
Cystic Fibrosis - Pipeline by AstraZeneca Plc, H2 2017
Cystic Fibrosis - Pipeline by Bayer AG, H2 2017
Cystic Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Cystic Fibrosis - Pipeline by Catabasis Pharmaceuticals Inc, H2 2017
Cystic Fibrosis - Pipeline by Celtaxsys Inc, H2 2017
Cystic Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H2 2017
Cystic Fibrosis - Pipeline by Cilian AG, H2 2017
Cystic Fibrosis - Pipeline by CRISPR Therapeutics, H2 2017
Cystic Fibrosis - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017
Cystic Fibrosis - Pipeline by DiscoveryBiomed Inc, H2 2017
Cystic Fibrosis - Pipeline by Editas Medicine Inc, H2 2017
Cystic Fibrosis - Pipeline by Eloxx Pharmaceuticals Ltd, H2 2017
Cystic Fibrosis - Pipeline by Enterprise Therapeutics Ltd, H2 2017
Cystic Fibrosis - Pipeline by Errant Gene Therapeutics LLC, H2 2017
Cystic Fibrosis - Pipeline by ethris GmbH, H2 2017
Cystic Fibrosis - Pipeline by Galapagos NV, H2 2017
Cystic Fibrosis - Pipeline by Gilead Sciences Inc, H2 2017
Cystic Fibrosis - Pipeline by Grifols SA, H2 2017
Cystic Fibrosis - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2017
Cystic Fibrosis - Pipeline by Horizon Pharma Plc, H2 2017
Cystic Fibrosis - Pipeline by ID Pharma Co Ltd, H2 2017
Cystic Fibrosis - Pipeline by Immun System IMS AB, H2 2017
Cystic Fibrosis - Pipeline by Insmed Inc, H2 2017
Cystic Fibrosis - Pipeline by Invion Ltd, H2 2017
Cystic Fibrosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Cystic Fibrosis - Pipeline by JHL Biotech Inc, H2 2017
Cystic Fibrosis - Pipeline by Johnson & Johnson, H2 2017
Cystic Fibrosis - Pipeline by Kamada Ltd, H2 2017
Cystic Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Cystic Fibrosis - Pipeline by La Jolla Pharmaceutical Company, H2 2017
Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H2 2017
Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc, H2 2017
Cystic Fibrosis - Pipeline by Lexicon Pharmaceuticals Inc, H2 2017
Cystic Fibrosis - Pipeline by Microbion Corp, H2 2017
Cystic Fibrosis - Pipeline by Mucokinetica Ltd, H2 2017
Cystic Fibrosis - Pipeline by Novabiotics Ltd, H2 2017
Cystic Fibrosis - Pipeline by Novartis AG, H2 2017
Cystic Fibrosis - Pipeline by OSE Immunotherapeutics, H2 2017
Cystic Fibrosis - Pipeline by Paranta Biosciences Ltd, H2 2017
Cystic Fibrosis - Pipeline by Parion Sciences Inc, H2 2017
Cystic Fibrosis - Pipeline by Pfizer Inc, H2 2017
Cystic Fibrosis - Pipeline by Pharmaxis Ltd, H2 2017
Cystic Fibrosis - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2017
Cystic Fibrosis - Pipeline by Polyphor Ltd, H2 2017
Cystic Fibrosis - Pipeline by Progenra Inc, H2 2017
Cystic Fibrosis - Pipeline by ProMetic Life Sciences Inc, H2 2017
Cystic Fibrosis - Pipeline by ProQR Therapeutics NV, H2 2017
Cystic Fibrosis - Pipeline by Protalix BioTherapeutics Inc, H2 2017
Cystic Fibrosis - Pipeline by Proteostasis Therapeutics Inc, H2 2017
Cystic Fibrosis - Pipeline by Pulmatrix Inc, H2 2017
Cystic Fibrosis - Pipeline by ReveraGen BioPharma Inc, H2 2017
Cystic Fibrosis - Pipeline by Savara Inc, H2 2017
Cystic Fibrosis - Pipeline by Sequoia Sciences Inc, H2 2017
Cystic Fibrosis - Pipeline by Shionogi & Co Ltd, H2 2017
Cystic Fibrosis - Pipeline by SolAeroMed Inc, H2 2017
Cystic Fibrosis - Pipeline by Synedgen Inc, H2 2017
Cystic Fibrosis - Pipeline by Synovo GmbH, H2 2017
Cystic Fibrosis - Pipeline by Translate Bio Inc, H2 2017
Cystic Fibrosis - Pipeline by Vanda Pharmaceuticals Inc, H2 2017
Cystic Fibrosis - Pipeline by Verona Pharma Plc, H2 2017
Cystic Fibrosis - Pipeline by Vertex Pharmaceuticals Inc, H2 2017
Cystic Fibrosis - Pipeline by Vironika LLC, H2 2017
Cystic Fibrosis - Dormant Projects, H2 2017
Cystic Fibrosis - Dormant Projects, H2 2017 (Contd.1), H2 2017
Cystic Fibrosis - Dormant Projects, H2 2017 (Contd.2), H2 2017
Cystic Fibrosis - Dormant Projects, H2 2017 (Contd.3), H2 2017
Cystic Fibrosis - Dormant Projects, H2 2017 (Contd.4), H2 2017
Cystic Fibrosis - Dormant Projects, H2 2017 (Contd.5), H2 2017
Cystic Fibrosis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Cystic Fibrosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

4D Molecular Therapeutics Inc
Achaogen Inc
Advanced Inhalation Therapies (AIT) Ltd
Alaxia SAS
AlgiPharma AS
Antabio SAS
Apteeus
Arch Biopartners Inc
Arcturus Therapeutics Inc
Aridis Pharmaceuticals LLC
AstraZeneca Plc
Bayer AG
Boehringer Ingelheim GmbH
Catabasis Pharmaceuticals Inc
Celtaxsys Inc
Chiesi Farmaceutici SpA
Cilian AG
CRISPR Therapeutics
Cyclacel Pharmaceuticals Inc
DiscoveryBiomed Inc
Editas Medicine Inc
Eloxx Pharmaceuticals Ltd
Enterprise Therapeutics Ltd
Errant Gene Therapeutics LLC
ethris GmbH
Galapagos NV
Gilead Sciences Inc
Grifols SA
Grupo Praxis Pharmaceutical SA
Horizon Pharma Plc
ID Pharma Co Ltd
Immun System IMS AB
Insmed Inc
Invion Ltd
Ionis Pharmaceuticals Inc
JHL Biotech Inc
Johnson & Johnson
Kamada Ltd
Kyorin Pharmaceutical Co Ltd
La Jolla Pharmaceutical Company
Lamellar Biomedical Ltd
Laurent Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc
Microbion Corp
Mucokinetica Ltd
Novabiotics Ltd
Novartis AG
OSE Immunotherapeutics
Paranta Biosciences Ltd
Parion Sciences Inc
Pfizer Inc
Pharmaxis Ltd
PhaseBio Pharmaceuticals Inc
Polyphor Ltd
Progenra Inc
ProMetic Life Sciences Inc
ProQR Therapeutics NV
Protalix BioTherapeutics Inc
Proteostasis Therapeutics Inc
Pulmatrix Inc
ReveraGen BioPharma Inc
Savara Inc
Sequoia Sciences Inc
Shionogi & Co Ltd
SolAeroMed Inc
Synedgen Inc
Synovo GmbH
Translate Bio Inc
Vanda Pharmaceuticals Inc
Verona Pharma Plc
Vertex Pharmaceuticals Inc
Vironika LLC
Skip to top


Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2017 US$ 2,000.00 Oct, 2017 · 278 pages

Ask Your Question

Cystic Fibrosis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: